These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 23644930)

  • 1. Clinical efficacy on fracture risk and safety of 0.5 mg or 1 mg/month intravenous ibandronate versus 2.5 mg/day oral risedronate in patients with primary osteoporosis.
    Nakamura T; Nakano T; Ito M; Hagino H; Hashimoto J; Tobinai M; Mizunuma H;
    Calcif Tissue Int; 2013 Aug; 93(2):137-46. PubMed ID: 23644930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg.
    Epstein S; Jeglitsch M; McCloskey E
    Curr Med Res Opin; 2009 Dec; 25(12):2951-60. PubMed ID: 19835464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of the comparative effectiveness of 3 oral bisphosphonates in a large managed care organization: adherence, fracture rates, and all-cause cost.
    Martin KE; Yu J; Campbell HE; Abarca J; White TJ
    J Manag Care Pharm; 2011 Oct; 17(8):596-609. PubMed ID: 21942301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical efficacy and safety of monthly oral ibandronate 100 mg versus monthly intravenous ibandronate 1 mg in Japanese patients with primary osteoporosis.
    Nakamura T; Ito M; Hashimoto J; Shinomiya K; Asao Y; Katsumata K; Hagino H; Inoue T; Nakano T; Mizunuma H;
    Osteoporos Int; 2015 Nov; 26(11):2685-93. PubMed ID: 26001561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ibandronate: A Review in Japanese Patients with Osteoporosis.
    Keating GM
    Drugs Aging; 2016 Apr; 33(4):295-303. PubMed ID: 26915075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of monthly intravenous ibandronate injections on vertebral or non-vertebral fracture risk in Japanese patients with high-risk osteoporosis in the MOVER study.
    Ito M; Tobinai M; Yoshida S; Hashimoto J; Nakamura T
    J Bone Miner Metab; 2017 Jan; 35(1):58-64. PubMed ID: 26614597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.
    Roux C; Reid DM; Devogelaer JP; Saag K; Lau CS; Reginster JY; Papanastasiou P; Bucci-Rechtweg C; Su G; Sambrook PN
    Osteoporos Int; 2012 Mar; 23(3):1083-90. PubMed ID: 21975559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation.
    Lewiecki EM; Babbitt AM; Piziak VK; Ozturk ZE; Bone HG
    Clin Ther; 2008 Apr; 30(4):605-21. PubMed ID: 18498910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial.
    Reid DM; Devogelaer JP; Saag K; Roux C; Lau CS; Reginster JY; Papanastasiou P; Ferreira A; Hartl F; Fashola T; Mesenbrink P; Sambrook PN;
    Lancet; 2009 Apr; 373(9671):1253-63. PubMed ID: 19362675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonvertebral fracture risk reduction with nitrogen-containing bisphosphonates.
    Hochberg MC
    Curr Osteoporos Rep; 2008 Sep; 6(3):89-94. PubMed ID: 18752769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.
    Harris ST; Watts NB; Genant HK; McKeever CD; Hangartner T; Keller M; Chesnut CH; Brown J; Eriksen EF; Hoseyni MS; Axelrod DW; Miller PD
    JAMA; 1999 Oct; 282(14):1344-52. PubMed ID: 10527181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE.
    Chesnut CH; Ettinger MP; Miller PD; Baylink DJ; Emkey R; Harris ST; Wasnich RD; Watts NB; Schimmer RC; Recker RR
    Curr Med Res Opin; 2005 Mar; 21(3):391-401. PubMed ID: 15811208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of monthly ibandronate versus weekly risedronate in preference, convenience, and bone turnover markers in Korean postmenopausal osteoporotic women.
    Chung YS; Lim SK; Chung HY; Lee IK; Park IH; Kim GS; Min YK; Kang MI; Chung DJ; Kim YK; Choi WH; Shong MH; Park JH; Byun DW; Yoon HK; Shin CS; Lee YS; Kwon NH
    Calcif Tissue Int; 2009 Nov; 85(5):389-97. PubMed ID: 19816648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.
    Chesnut CH; Skag A; Christiansen C; Recker R; Stakkestad JA; Hoiseth A; Felsenberg D; Huss H; Gilbride J; Schimmer RC; Delmas PD;
    J Bone Miner Res; 2004 Aug; 19(8):1241-9. PubMed ID: 15231010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy, tolerability and safety of once-monthly administration of 75mg risedronate in Japanese patients with involutional osteoporosis: a comparison with a 2.5mg once-daily dosage regimen.
    Hagino H; Kishimoto H; Ohishi H; Horii S; Nakamura T
    Bone; 2014 Feb; 59():44-52. PubMed ID: 24184313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data.
    McClung MR; Zanchetta JR; Racewicz A; Roux C; Benhamou CL; Man Z; Eusebio RA; Beary JF; Burgio DE; Matzkin E; Boonen S; Delmas P
    Osteoporos Int; 2013 Jan; 24(1):293-9. PubMed ID: 22752050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk reduction of non-vertebral fractures with intravenous ibandronate: post-hoc analysis from DIVA.
    Sambrook P; Cranney A; Adachi JD
    Curr Med Res Opin; 2010 Mar; 26(3):599-604. PubMed ID: 20055751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension.
    Bianchi G; Czerwinski E; Kenwright A; Burdeska A; Recker RR; Felsenberg D
    Osteoporos Int; 2012 Jun; 23(6):1769-78. PubMed ID: 21975558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the efficacy between once-monthly oral ibandronate and risedronate among Korean women with osteoporosis: a nationwide population-based study.
    Lee DR; Lee J
    Osteoporos Int; 2019 Mar; 30(3):659-666. PubMed ID: 30535785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term fracture rates seen with continued ibandronate treatment: pooled analysis of DIVA and MOBILE long-term extension studies.
    Miller PD; Recker RR; Harris S; Silverman S; Felsenberg D; Reginster J; Day BM; Barr C; Masanauskaite D
    Osteoporos Int; 2014 Jan; 25(1):349-57. PubMed ID: 24136103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.